Melanoma future or investigational therapies

	Melanoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Melanoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Genetic Counselling
Cost-Effectiveness of Therapy
Future or Investigational Therapies
2019 AAD Guidelines for management of Primary Cutaneous Melanoma (CM)
Guidelines for Diagnosis of Primary CM
Guidelines for Treatment of Primary CM
Guidelines for management of Primary CM in Pregnancy
Case Studies
Case #1
Melanoma future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Melanoma future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Melanoma future or investigational therapies
CDC on Melanoma future or investigational therapies
Melanoma future or investigational therapies in the news
Blogs on Melanoma future or investigational therapies
Directions to Hospitals Treating Melanoma
Risk calculators and risk factors for Melanoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anum Ijaz M.B.B.S., M.D.[2]

Future Techniques[edit | edit source]

Optical Coherence Tomography (OCT)

In addition to identifying high-risk patients, researchers also want to identify high-risk lesions within a given patient. Many new technologies, such as optical coherence tomography (OCT), are being developed to accomplish this. OCT allows pathologists to view 3-D reconstructions of the skin and offers more resolution than past techniques could provide. In vivo confocal microscopy and fluorescently tagged antibodies are also proving to be valuable diagnostic tools.

Tumor-informed circulating DNA (ctDNA) Assay

Small cohort studies demonstrate that ctDNA positivity may predict relapse, detected either on imaging (radiographic) or by symptoms and exam (clinical). ^[1]. Ongoing studies are evaluating whether ctDNA can detect early relapse in resected melanoma, identifying molecular recurrence (tumor DNA in blood before clinical or radiographic evidence) to guide earlier treatment. [3]

References[edit | edit source]

↑ Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A (June 2023). "Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients". Cancer. 129 (11): 1723–1734. doi:10.1002/cncr.34716. PMID 36869646 Check |pmid= value (help).

Template:WikiDoc Sources

[pmid36869646-1] Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, Martin J, Bui KM, Palsuledesai CC, Malhotra M, Olshan P, Markowitz J, Khushalani NI, Tarhini AA, Messina JL, Aleshin A (June 2023). "Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients". Cancer. 129 (11): 1723–1734. doi:10.1002/cncr.34716. PMID 36869646 Check |pmid= value (help).

[1]